Urolithin Supplement in Prostate Cancer

Purpose of this Study

We are doing this study is to compare the effects of Urolithin A and placebo (an inactive substance with no medicinal properties) on the biological composition of the prostate in men with prostate cancer. In this study, you will have an equal chance of either taking Urolithin A or placebo.

Who Can Participate?

Eligibility

Men ages 18+ who:
  • Were diagnosed with prostate cancer within 6 months of joining the study
  • Are scheduled to have surgery to remove the prostate
  • Have not received any hormonal therapy
  • Are not currently using any Urolithin A supplements (e.g., Mitopure)
For more information, contact the study team at denise.lech@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Non-binary or gender fluid
Transgender male
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will get a random assignment (like a coin flip) to either take Urolithin A or a placebo. Urolithin A is a supplement that is found naturally in certain fruits and nuts, and it can also be produced by our gut bacteria. After you get your assignment, you will:
  • Take Urolithin A or the placebo twice a day for 3-6 weeks before your scheduled surgery
  • Keep a diary about any possible side effects you have while taking your assigned pills
  • Have some tissue from your prostate sampled for testing
We will check in on you after your surgery to see how you are doing and close your participation in the study. Study website: https://www.nucancerprevention.org/ihaveprostatecancer

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY

Principal Investigator

Judd
Moul

Protocol Number

PRO00112750

NCT ID

NCT06022822

Phase

II

Enrollment Status

Open to Enrollment